OmniComm’s TrialMaster Phase 1 Version Chosen for 7 Studies by Catalyst Pharmaceutical Research

OmniComm’s TrialMaster Phase 1 Version Chosen for 7 Studies by Catalyst Pharmaceutical Research

OmniComm Systems, Inc. (OTC BB: OMCM),

one of the fastest growing companies in the EDC marketplace, announced

today that the company’s TrialMaster Ph. 1 EDC product has been selected by

Catalyst Pharmaceutical Research for 7 phase 1 studies conducted on behalf

of 5 different sponsor companies in just the first quarter of 2006.

“Historically the use of EDC for Phase 1 studies has been relatively low,

primarily because of the very issues OmniComm’s TrialMaster Ph. 1 is now

able to address: rapid set-up time, easy to customize platform, smooth

integration with laboratory and other external data, low cost,” said

Richard Anthony, PhD, Catalyst Chairman and CEO. “Since Catalyst is a

rapidly growing full service CRO, we rely on technology driven products

like TrialMaster Ph. 1 to enable us to perform more studies, faster, with

greater data quality compared to traditional methods, all at a lower cost

to our sponsors.”

Randy Smith, CTO of OmniComm added that he sees an increasing interest in

TrialMaster Ph.1. “Our clients are taking advantage of the benefits of

real-time insight into study data which allows faster stop-go decisions.”

Another appealing aspect of OmniComm’s TrialMaster Ph.1 is that it uses a

flat fee for all Phase 1 studies, including setup, on-demand import and

data extracts, reporting, support, and monthly maintenance. “We see EDC as

a commonly used tool for the Phase 1 market in the coming years and

OmniComm is very well positioned to become a leader in that market.”

About Catalyst Pharmaceutical Research LLC

Catalyst Pharma Group, Inc ( ), is an integrated

clinical research organization providing services to meet the needs of

companies seeking to develop, approve, and market pharmaceuticals in the

U.S. We specialize in providing contiguous, strategic approaches to

cost-effective drug development through three divisions: Healthcare

Discoveries Inc. ( ) industry dedicated Phase

I/IIa facilities; Catalyst Pharmaceutical Research Inc.

( ), a full service CRO for clinical research,

biostatistics and data processing, regulatory, and licensing support for

pharmaceutical development; and Adept LTD ( ), a

Birmingham, UK based project management team servicing EU and UK deployed

clinical development programs.

About OmniComm Systems, Inc.

OmniComm Systems, Inc. ( ) is one of the fastest growing

companies in the EDC market place targeting its product TrialMaster® to

the pharmaceutical, medical device and biotechnology companies as well as

CROs. OmniComm’s growing base of satisfied customers is a direct result of

OmniComm’s employees’ commitment to on-time, quality and within budget


The TrialMaster ( ) system, the core product of OmniComm,

provides trial sponsors with a 21 CRF Part 11 compliant Internet-based data

and trial management solution that greatly increases the efficiency,

security and integrity of clinical research data and thus significantly

reduces the time and expense involved in conducting clinical studies.

Safe Harbor Disclaimer

Statements about OmniComm’s future expectations, including without

limitation, future revenues and earnings, plans and objectives for the

future operations, future agreements, future economic performance,

operations and all other statements in this press release other than

historical facts are “forward-looking statements” within the meaning of

Section 27A of the Securities Act of 1933, Section 21E of the Securities

Exchange Act of 1934, and as that term is defined in the Private Securities

Litigation Reform Act of 1995. OmniComm intends that such forward-looking

statements be subject to the Safe Harbors created thereby. Since these

statements involve risks and uncertainties, including but not limited to

economic competitive, governmental, contractual and technological factors

affecting OmniComm’s operations, markets and profitability, actual results

could differ materially and adversely from the expected results.

For more info, please contact

Rusty Beardsley

Sr. VP Marketing and Sales

OmniComm Systems, Inc.


Email Contact